Okay, let's tackle this question. The patient is a 59-year-old male with hemoglobin consistently at 18.0 g/dL on three occasions. The resident wants to rule out Polycythemia Vera (PV). The question is asking which investigation is most relevant.

First, I need to recall what PV is. PV is a myeloproliferative neoplasm characterized by increased red blood cell mass. The key here is that PV is a clonal disorder, so investigations should aim to confirm the diagnosis and differentiate it from other causes of erythrocytosis, like secondary polycythemia (due to hypoxia, tumors, etc.) or relative polycythemia (like dehydration).

The core concept here is understanding the diagnostic criteria for PV. The WHO criteria include elevated hemoglobin, increased red cell mass, and certain laboratory findings. The most specific test for PV is the JAK2 V617F mutation, which is present in about 95% of cases. Other mutations like CALR or MPL might also be considered, but JAK2 is the most common.

So the correct answer would be a test for the JAK2 mutation. Let's look at the options. The user didn't list them, but typical options might include CBC, peripheral smear, JAK2 mutation testing, or EPO levels. If the options are similar, the correct one is the JAK2 test.

Why are other options incorrect? CBC and peripheral smear can show features like increased RBCs, but they don't confirm PV. EPO levels might be low in PV because the cells are insensitive to EPO, but that's not as specific as the mutation test. Reticulocyte count might be elevated in other conditions but not specific. So the JAK2 mutation is the most relevant investigation.

**Core Concept**
Polycythemia Vera (PV) is a myeloproliferative neoplasm characterized by clonal overproduction of red blood cells, often with associated thrombocytosis and leukocytosis. Diagnosis requires confirmation of a **JAK2 V617F mutation** (present in 95% of cases) or other driver mutations (CALR, MPL) to distinguish it from secondary erythrocytosis.

**Why the Correct Answer is Right**
The **JAK2 V617F mutation test** is the most specific and sensitive investigation for PV. This mutation leads to constitutive activation of the JAK-STAT signaling pathway, driving uncontrolled erythropoiesis. Confirming this mutation differentiates PV from reactive erythrocytosis (e.g., due to hypoxia, tumors, or renal disease), which lacks clonal markers. Additional tests like serum erythropoietin (EPO) levels (suppressed in PV) and red cell mass measurements may aid, but the JAK2 mutation is the gold standard.

**Why Each Wrong Option is Incorrect**
**Option A:** *Complete blood count (CBC)* shows elevated Hb and RBC count but is nonspecific—seen in both PV and secondary polycythemia.
**Option B:** *Peripheral smear* may reveal leukocytosis or teardrop cells but does not confirm clonality.
**Option C:** *EPO level* testing is supportive (low EPO

✓ Correct Answer: C. Red cell mass